Welcome to our dedicated page for agilon health SEC filings (Ticker: AGL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
agilon health, inc. filings document the company’s value-based healthcare services business, governance matters, capital structure and operating results. Form 8-K reports furnish quarterly and annual financial results, Regulation FD investor presentation materials, executive appointment and compensation arrangements, and material definitive agreements, including amendments to the company’s credit agreement.
Definitive proxy statements cover shareholder voting matters, board governance and executive compensation. The filing record also includes capital-structure disclosures, such as a certificate amendment related to a reverse stock split of common stock, along with risk-factor and material-event disclosures relevant to agilon’s physician-partnership model and payor contracting environment.
agilon health, inc. announced that Chief Technology Officer Girish Venkatachaliah will leave the company effective August 1, 2026. His departure is governed by a Severance Agreement and General Release that becomes effective eight days after he signs it.
Under this agreement, he is entitled to $766,063 in cash severance, paid in installments over twelve months after the separation date. He will also continue to vest, through April 30, 2027, in his 2025 transformation equity award and other outstanding time- and service-vesting restricted stock units scheduled to vest on or before that date, subject to any performance-based vesting conditions. Venkatachaliah is expected to enter a Consulting Agreement to provide transition consulting services from August 1, 2026 through December 31, 2026, for no consideration other than this continued equity vesting.
agilon health, inc. Chief Financial Officer Jeffrey A. Schwaneke reported a routine tax-related share disposition. On the reported date, 2,311 shares of Common Stock were withheld by the company to satisfy income tax withholding and remittance obligations tied to the net settlement of restricted stock units, and this was not an open-market sale. After this withholding, Schwaneke directly holds 138,031 shares of Common Stock, which the disclosure notes includes restricted stock units.
agilon health, inc. Chief Legal Officer Denise Zamore reported a small tax-related share disposition. On the reported date, 485 shares of common stock were withheld by the company to cover income tax obligations from the net settlement of restricted stock units, and this did not involve an open-market sale. After this withholding, she held 66,112 shares directly, including restricted stock units.
Wulf John William reported acquisition or exercise transactions in this Form 4 filing.
agilon health, inc. director John William Wulf received an equity award of 2,133 shares in the form of restricted stock units as compensation. These units vest in full on June 2, 2027, subject to his continued service as a director. After this grant, he beneficially owns 16,765 shares, including restricted stock units, reflecting a 1-for-25 reverse stock split of the company’s common stock that became effective on March 30, 2026.
WILLIAMS RONALD A reported acquisition or exercise transactions in this Form 4 filing.
agilon health, inc. director Ronald A. Williams received a grant of 2,133 restricted stock units of common stock, with no cash price per share reported. These units vest in full on June 2, 2027, subject to his continued service as a director.
After this award, Williams beneficially owns 149,141 shares of agilon health common stock, including restricted stock units. The holdings figure reflects a 1-for-25 reverse stock split of the company’s issued and outstanding common stock that became effective on March 30, 2026.
McLoughlin Karen reported acquisition or exercise transactions in this Form 4 filing.
agilon health, inc. director Karen McLoughlin reported receiving an equity award of 2,133 shares of common stock in the form of restricted stock units. These units vest in full on June 2, 2027, if she continues serving as a director through that date.
After giving effect to a 1-for-25 reverse stock split effective March 30, 2026, her beneficial ownership, including restricted stock units, totals 8,207 shares of common stock.
agilon health, inc. director Diana McKenzie received an equity grant in the form of restricted stock units. She acquired 2,133 shares of Common Stock at no cash cost as a grant or award, increasing her direct beneficial ownership to a total of 7,633 shares, including restricted stock units. The RSUs vest in full on June 2, 2027, as long as she continues to serve as a director. The ownership figure reflects the company’s 1-for-25 reverse stock split of its common stock that became effective on March 30, 2026.
Mansukani Sharad reported acquisition or exercise transactions in this Form 4 filing.
agilon health, inc. director Sharad Mansukani received a grant of 2,133 shares of Common Stock in the form of restricted stock units. These units vest in full on June 2, 2027, contingent on his continued service as a director.
After this award, he beneficially owns 56,242 shares, which include restricted stock units and reflect the company’s 1-for-25 reverse stock split that became effective on March 30, 2026. This filing reflects routine equity compensation rather than an open‑market trade.
Battaglia Silvana reported acquisition or exercise transactions in this Form 4 filing.
agilon health, inc. director Silvana Battaglia received an equity award of 2,133 restricted stock units, granted at no cash cost and reported as Common Stock. These RSUs vest in full on June 2, 2027, if she continues serving as a director. Following this grant, her beneficial ownership is 7,926 shares, which includes restricted stock units and reflects a 1-for-25 reverse stock split that became effective on March 30, 2026.
agilon health, inc. reported the results of its annual stockholder meeting held on June 2, 2026. Stockholders elected three Class II directors—Diana McKenzie, Karen McLoughlin, and Ronald Williams—to serve until the 2029 annual meeting.
Stockholders also ratified Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. In addition, stockholders approved, on a non-binding advisory basis, the compensation of the company’s named executive officers.